Cardiovascular outcomes trials and why they reshape pharmacology

Why CVOTs exist

The FDA's 2008 CVOT guidance for diabetes drugs was a regulatory response to rosiglitazone — a thiazolidinedione that improved glycemic control but was associated with increased cardiovascular events in pooled analyses. The case made clear that improving HbA1c (a surrogate endpoint) doesn't automatically translate to fewer cardiovascular events (the actual outcome). Surrogate endpoints can dissociate from clinical outcomes in ways that matter.

The CVOT requirement transformed metabolic drug development. Every new diabetes therapy now requires a cardiovascular outcomes trial demonstrating no harm — and increasingly, demonstrating actual cardiovascular benefit, which is what reshapes the class.

What CVOTs in the GLP-1 class have shown

The accumulated CVOT evidence for GLP-1 is among the strongest of any drug class:

• LEADER (liraglutide, 2016) — 13% reduction in major adverse cardiovascular events (MACE) in T2D patients with cardiovascular disease.
• SUSTAIN-6 (semaglutide, 2016) — 26% reduction in MACE in T2D-CVD patients.
• REWIND (dulaglutide, 2019) — 12% reduction in MACE in T2D, including primary-prevention patients.
• SELECT (semaglutide, 2023) — 20% reduction in MACE in obesity (without diabetes) with established CVD. The first CVOT for an obesity indication.
• FLOW (semaglutide, 2024) — Renal outcomes evidence in T2D-CKD.

The pattern is consistent and substantial. GLP-1 receptor agonists reduce hard cardiovascular endpoints across multiple molecules, multiple populations, and multiple trials — a level of evidence rare in modern pharmacology.

Why CVOTs change practice in ways surrogate-endpoint trials don't

Several reasons:

1. Hard endpoints are interpretable directly. "Reduces myocardial infarction by 25%" is what clinicians and patients ultimately want to know. HbA1c reduction is a means to that end, not the end itself.
2. The signal is integrated over long follow-up. CVOTs typically run 2-5 years with thousands of patients, integrating drug effects on multiple parallel cardiovascular pathways (lipids, blood pressure, inflammation, endothelial function, weight) into a single hard-outcome readout.
3. Indication expansion follows. A drug with a positive CVOT in T2D-CVD often gains a separate cardiovascular-disease indication. SELECT did this for semaglutide in obesity.
4. Reimbursement and guidelines align. Cardiovascular guideline bodies (ACC, ESC) update recommendations based on CVOT data; payors align coverage with hard-outcome evidence.

The CVOT trajectory for tirzepatide and the future of the class

SURPASS-CVOT is the ongoing cardiovascular outcomes trial for tirzepatide. The expected readout is one of the most anticipated metabolic-pharmacology data points of the decade. Possible outcomes:

• Tirzepatide demonstrates non-inferiority to placebo (no harm). This is the regulatory floor and is widely expected given the GLP-1-class CVOT precedent.
• Tirzepatide demonstrates superiority (reduces MACE). If so, it would be the first dual-agonist with a positive CVOT, which would parallel the GLP-1-class pattern at the deeper-weight-loss molecular level.
• Tirzepatide demonstrates differentiation from semaglutide. A SURPASS-CVOT vs SELECT cross-trial comparison wouldn't be a head-to-head, but if magnitudes of cardiovascular benefit differ substantially, it would shape how the molecules are positioned in patients with established CVD.

Beyond tirzepatide, retatrutide's CVOT will be the next major data point — and so will the CVOTs for the dual GLP-1/glucagon agonists currently in late-stage trials.

What the CVOT framework implies for other peptide classes

The CVOT-driven evidence-grading is starting to apply beyond metabolic peptides:

• NASH and liver disease therapeutics — long-term hepatic and cardiovascular outcomes are now expected for any major MASH therapy.
• Obesity muscle-preservation therapies — bimagrumab + GLP-1 trials will need to demonstrate not just lean-mass preservation but also long-term outcomes (cardiovascular, fracture risk, all-cause mortality).
• Longevity-focused peptide therapeutics — by definition require very long follow-up, but the CVOT logic (hard-endpoint evidence, multi-year follow-up) is the appropriate framework.

For peptide classes that haven't yet generated CVOT-level evidence — most of the research peptides discussed on this site — the absence is informative. It tells you these compounds haven't been studied to the standard that would let clinicians and payors confidently recommend them.